Trial intelligence / Profile preview

Neratinib after trastuzumab in early HER2-positive breast cancer

2008-007345-31Phase 3Completed

Sponsor

Puma Biotechnology, Inc.

Start

Jun 2009

Modality

Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules

Countries

1